Until about 15 years ago, most men diagnosed with prostate cancer — no matter how aggressive — underwent surgery or radiation ...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...

NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that ...

The principal investigator of the trial, Ellis is a radiation oncologist and physician-scientist at the Tampa General Cancer Institute, Tampa General Hospital and serves as direct ...

Men with prostate cancer can safely exercise, benefiting from reduced treatment side effects, improved mental health, and ...

Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

Jesse Bennett, a two-time prostate cancer survivor and Morgan State University health education graduate, uses his journey to inspire other men to take charge of their health by learning their PSA ...

Experts say the first approved neoantigen cancer vaccines might be available by 2029. This timeline gives Ghana a chance to ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...